Questions: Neurobiological Mechanisms of Mood Disorders

Question 1

Antidepressants that block serotonin reuptake (SSRIs) increase synaptic serotonin within hours of the first dose, yet most patients don't experience clinical improvement for 2–4 weeks. What does this delay most strongly suggest?

• A. SSRIs are correcting a serotonin deficiency, but patients are slow to notice the biochemical improvement
• B. The therapeutic effect depends on downstream adaptive changes — receptor desensitization, increased BDNF expression, and new synaptic growth — that take weeks to develop
• C. SSRIs need to accumulate to therapeutic blood levels before they can be effective, which takes several weeks
• D. The delay is a placebo effect; SSRIs' actual biological action is immediate but patients are slow to trust the medication

Answer: (B)

If depression were simply a monoamine deficiency, restoring those levels quickly should produce rapid improvement — but it doesn't. The 2–4 week delay is the strongest argument that the therapeutic mechanism is not monoamine restoration per se, but rather the downstream cascades that monoamines activate over time: receptor desensitization, upregulation of the cAMP-PKA-CREB pathway, increased BDNF expression, and ultimately synaptic plasticity and hippocampal neurogenesis. New neurons and synapses take weeks to mature, which aligns with the clinical timeline.

Question 2

Chronic stress elevates cortisol, which damages the hippocampus. Which mechanism creates a self-perpetuating vicious cycle?

• A. Cortisol stimulates the amygdala to produce more stress, which triggers more cortisol release indefinitely
• B. Hippocampal damage impairs the glucocorticoid feedback receptors that normally shut down cortisol secretion, leaving the HPA axis chronically hyperactive
• C. Cortisol destroys norepinephrine neurons in the locus coeruleus, which then cannot inhibit the HPA axis
• D. High cortisol permanently destroys the pituitary gland, which can no longer regulate adrenal output

Answer: (B)

The hippocampus contains glucocorticoid receptors that provide negative feedback to the HPA axis — detecting high cortisol and signaling the hypothalamus to reduce CRH secretion, shutting down cortisol release. When sustained high cortisol damages hippocampal neurons, this feedback mechanism is impaired: the HPA axis stays active longer, releasing more cortisol, causing more hippocampal damage, further impairing feedback. This vicious cycle helps explain why early trauma sensitizes the stress system for decades and why depression with HPA dysregulation is harder to treat.

Question 3

The monoamine hypothesis of depression is simply wrong — SSRIs and other monoaminergic antidepressants do not actually work through their effects on serotonin, dopamine, or norepinephrine.

• T. True
• F. False

Answer: False

The monoamine hypothesis is *incomplete*, not wrong. Monoaminergic drugs do have antidepressant effects, and monoamine systems are genuinely dysregulated in depression. The problem is that simple deficiency/restoration doesn't explain the treatment delay or why depleting monoamines doesn't reliably cause depression in healthy people. The current view is that monoamine effects are real but work *through* downstream cascades — the cAMP-CREB pathway, BDNF, neuroplasticity — rather than by directly correcting a deficiency. It is a useful framework requiring augmentation, not replacement.

Question 4

Reduced BDNF expression in the hippocampus and prefrontal cortex is associated with depression, and antidepressants restore BDNF levels — consistent with the neuroplasticity hypothesis.

• T. True
• F. False

Answer: True

This is well-supported and forms a key pillar of the neuroplasticity hypothesis. BDNF promotes neuronal survival, synaptic plasticity, and hippocampal neurogenesis. Stress and depression reduce BDNF expression; antidepressants, electroconvulsive therapy, and exercise all increase it. The timeline of BDNF restoration — weeks — matches the clinical timeline of antidepressant response, providing stronger support for the neuroplasticity hypothesis than for simple monoamine restoration.

Question 5

Why does the neuroplasticity hypothesis of depression better explain antidepressant action than the original monoamine deficiency hypothesis?

Model answer: The monoamine hypothesis predicts rapid improvement once monoamine levels are restored — but clinical improvement takes 2–4 weeks despite monoamines rising within hours. The neuroplasticity hypothesis explains this delay: antidepressants activate the cAMP-PKA-CREB signaling cascade downstream of monoamine receptors, which increases BDNF expression and promotes synaptic remodeling and hippocampal neurogenesis. These structural changes take weeks to develop, matching the actual clinical timeline. The hypothesis also explains why exercise and ECT — which also increase BDNF — have antidepressant effects.

The treatment delay is the Achilles' heel of the simple deficiency model and the primary motivation for the neuroplasticity hypothesis. It shifts the focus from 'how much neurotransmitter is in the synapse' to 'what adaptive changes in neural circuitry does that neurotransmitter ultimately drive' — a fundamentally different and better-supported account of antidepressant action.